BRCA1/BRCA2-Associated Pancreatic Cancer: Case Series

The presence of a mutation in the BRCA1/2 genes makes it possible to use platinum drugs and PARP inhibitors in patients with pancreatic cancer. Conducting molecular genetic testing allows you to assess the risk of developing malignant neoplasms in a patient and his relatives. We present a series of clinical cases of patients with pancreatic cancer associated with BRCA 1/2. Conducting molecular genetic testing allows you to assess the risk of developing malignant neoplasms in a patient and his relatives. A burdened family history is an indication for molecular genetic diagnosis to identify a pathogenic variant and the possibility of prescribing observation to detect a malignant neoplasm at an early stage.